Treatment of Inguinal Lymph Node Metastases in Patients with Rectal Adenocarcinoma.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
08
10
2018
pubmed:
7
2
2019
medline:
10
7
2019
entrez:
7
2
2019
Statut:
ppublish
Résumé
Inguinal lymph node metastases (ILNM) from rectal adenocarcinoma are rare and staged as systemic disease. This study aimed to provide insight into the treatment and prognosis of ILNM from rectal adenocarcinoma. All patients with a diagnosis of synchronous or metachronous ILNM from rectal adenocarcinoma between January 2005 and March 2017 were retrospectively reviewed. The study identified 27 patients with ILNM (15 with synchronous and 12 with metachronous disease). After discussion by a multidisciplinary tumor board, 19 patients were treated with curative intent, 17 of whom underwent inguinal lymph node dissection. Of the 17 patients, 12 had locally advanced rectal cancer (LARC) with isolated ILNM, 3 had LARC and metastases elsewhere, and 2 had locally recurrent rectal cancer (LRRC). The median overall survival (OS) for all the patients treated with curative intent was 27 months [95% confidence interval (CI) 11.6-42.4 months], with a 5-year OS rate of 34%. The median OS for the patients with LARC and isolated ILNM (n = 12) was 74 months (95% CI 18.0-130.0 months), with a 5-year OS rate of 52%. All the patients with metastases elsewhere (n = 3) or LRRC (n = 2) experienced recurrent systemic disease. Eight patients were treated with palliative intent. The median OS for this group was 13 months (95% CI 1.9-24.1 months), with a 3-year OS rate of 0%. Clinicians should not consider ILNM as an incurable systemic disease. Patients with primary rectal cancer and solitary ILNM who were eligible for curative surgical treatment had a 5-year survival rate of 52%. The prognosis for patients with additional systemic metastases or LRRC is worse, and the benefit of surgery is unclear.
Sections du résumé
BACKGROUND
BACKGROUND
Inguinal lymph node metastases (ILNM) from rectal adenocarcinoma are rare and staged as systemic disease. This study aimed to provide insight into the treatment and prognosis of ILNM from rectal adenocarcinoma.
METHODS
METHODS
All patients with a diagnosis of synchronous or metachronous ILNM from rectal adenocarcinoma between January 2005 and March 2017 were retrospectively reviewed.
RESULTS
RESULTS
The study identified 27 patients with ILNM (15 with synchronous and 12 with metachronous disease). After discussion by a multidisciplinary tumor board, 19 patients were treated with curative intent, 17 of whom underwent inguinal lymph node dissection. Of the 17 patients, 12 had locally advanced rectal cancer (LARC) with isolated ILNM, 3 had LARC and metastases elsewhere, and 2 had locally recurrent rectal cancer (LRRC). The median overall survival (OS) for all the patients treated with curative intent was 27 months [95% confidence interval (CI) 11.6-42.4 months], with a 5-year OS rate of 34%. The median OS for the patients with LARC and isolated ILNM (n = 12) was 74 months (95% CI 18.0-130.0 months), with a 5-year OS rate of 52%. All the patients with metastases elsewhere (n = 3) or LRRC (n = 2) experienced recurrent systemic disease. Eight patients were treated with palliative intent. The median OS for this group was 13 months (95% CI 1.9-24.1 months), with a 3-year OS rate of 0%.
CONCLUSION
CONCLUSIONS
Clinicians should not consider ILNM as an incurable systemic disease. Patients with primary rectal cancer and solitary ILNM who were eligible for curative surgical treatment had a 5-year survival rate of 52%. The prognosis for patients with additional systemic metastases or LRRC is worse, and the benefit of surgery is unclear.
Identifiants
pubmed: 30725310
doi: 10.1245/s10434-019-07191-4
pii: 10.1245/s10434-019-07191-4
pmc: PMC6399178
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1134-1141Références
J Surg Oncol. 1999 Mar;70(3):177-80
pubmed: 10102348
Dis Colon Rectum. 1999 Nov;42(11):1464-6
pubmed: 10566535
Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):741-7
pubmed: 11597817
BMJ. 2004 Nov 27;329(7477):1272-6
pubmed: 15564260
Ann Surg. 1942 Aug;116(2):200-16
pubmed: 17858082
Colorectal Dis. 2010 Apr;12(4):312-5
pubmed: 19250258
Dis Colon Rectum. 1990 Mar;33(3):212-6
pubmed: 2311465
Dis Colon Rectum. 2013 May;56(5):535-50
pubmed: 23575392
Int J Colorectal Dis. 2013 Dec;28(12):1675-80
pubmed: 23836116
Ann Oncol. 2014 Sep;25 Suppl 3:iii1-9
pubmed: 25190710
Radiat Oncol. 2014 Dec 23;9:296
pubmed: 25533887
Ann Surg Oncol. 2017 Feb;24(2):330-339
pubmed: 27519351
Ann Oncol. 2017 Jul 1;28(suppl_4):iv22-iv40
pubmed: 28881920
Ann Surg. 1981 Mar;193(3):372-6
pubmed: 7212799
Am J Surg. 1994 Sep;168(3):285-7
pubmed: 8080070